879093-08-0

Usage

Uses

Used in Pharmaceutical Industry:
2,5-DIFLUORO-4-METHOXYBENZALDEHYDE is used as an intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs with specific therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, 2,5-DIFLUORO-4-METHOXYBENZALDEHYDE is utilized as a precursor in the production of agrochemicals, aiding in the creation of compounds that can enhance crop protection and yield.
Used in Organic Synthesis:
2,5-DIFLUORO-4-METHOXYBENZALDEHYDE is employed as a reagent in various organic synthesis processes, facilitating the creation of a range of organic compounds for different applications.
Used in Chemical Research and Development:
2,5-DIFLUORO-4-METHOXYBENZALDEHYDE is used as a valuable tool in chemical research and development due to its distinctive structure, which allows for exploration of new chemical reactions and mechanisms.

InChI:InChI=1/C8H6F2O2/c1-12-8-3-6(9)5(4-11)2-7(8)10/h2-4H,1H3

Upstream product

• 922719-76-4 (2,5-difluoro-4-methoxyphenyl)methanol 
• 68-12-2 N,N-dimethyl-formamide 
• 104197-14-0 5-bromo-1,3-difluoro-2-methoxy-benzene 
• 486424-36-6 4-bromo-2,5-difluoro phenol 
• 2713-31-7 2,5-difluorophenol 
• 202865-60-9 1-bromo-2,5-difluoro-4-methoxybenzene 

Downstream Products

• 873373-81-0 1-(bromomethyl)-2,5-difluoro-4-methoxybenzene 
• 922719-76-4 (2,5-difluoro-4-methoxyphenyl)methanol 

Relevant academic research and scientific papers

AGONISTS OF GPR40

The present invention relates to compounds that have the ability to modulate the activity of GPR40 and are there-fore useful in the treatment of GPR40 related disorders. In addition the invention relates to the compounds, methods for their preparation, pharmaceutical compositions containing the compounds and the uses of these compounds in the treatment of certain disorders related to GPR40 activity.

PYRIDAZINONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT

It is to provide a novel pyridazinone derivative represented by the following general formula (1), which is useful as a pharmaceutical and has a phosphodiesterase inhibitory action: wherein R1 represents H or C1-6 alkyl, each of R2 and R3 represents H, X, C1-6 alkoxy, Z represents O or S, and A represents AA or BB, wherein AA represents: and BB represents: wherein R4 represents H or C1-6 alkyl, and each of R5 and R6 represents C1-6 alkyl.

PYRAZOLONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT

It is to provide a novel pyrazolone derivative represented by the following general formula (1), which is useful as a pharmaceutical and has a phosphodiesterase inhibitory action: wherein R1,R2: C1-6 alkyl; R3,R4: H, X, C1-6 alkoxy; Z:O, S; A:AA, BB, wherein AA represents wherein BB represents wherein R5: H, C1-6 alkyl ; R6,R7: C1-6 alkyl.

PHARMACEUTICAL COMPOSITION COMPRISING A PYRAZOLE-O-GLUCOSIDE DERIVATIVE

The invention relates toa pharmaceutical composition comprising a pyrazole-O-glucoside derivative selected from the group of compounds (1) to (29) according to claim 1 in combination with at least one second therapeutic agent which is suitable in the trea

METHODS FOR PREVENTING AND TREATING METABOLIC DISORDERS AND NEW PYRAZOLE-O-GLYCOSIDE DERIVATIVES

The invention relates to methods for preventing or treating metabolic disorders, for improving glycemic control, for preventing progression from impaired glucose tolerance, insulin resistance and/or from metabolic syndrome to type 2 diabetes mellitus, for

Therapeutic diphenyl ether ligands

This invention is directed to compounds of formula Ia, Ib or Ic and to pharmaceutical compositions thereof: or a prodrug thereof and a pharmaceutically acceptable carrier, wherein the R groups are defined in the specification; and, in which the dashed line represents an optional double bond. The invention is also directed to methods of treating, diagnosing, and preventing disorders of the central nervous system that are associated with 5HT receptors, including obesity, attention deficit disorder, migraine, depression, epilepsy, anxiety, Alzheimer's disease, withdrawal from drug abuse, pain, schizophrenia, stress-related disorders, panic disorder, sleep disorders, phobias, obsessive compulsive disorder, post-traumatic-stress syndrome, immune system depression, stress-induced gastrointestinal dysfunction, stress-induced cardiovascular dysfunction, and sexual dysfunction.